Edition:
India

ADMA Biologics Inc (ADMA.OQ)

ADMA.OQ on NASDAQ Stock Exchange Capital Market

3.17USD
2:29am IST
Change (% chg)

$0.27 (+9.31%)
Prev Close
$2.90
Open
$2.92
Day's High
$3.19
Day's Low
$2.90
Volume
28,746
Avg. Vol
25,009
52-wk High
$6.10
52-wk Low
$2.02

Chart for

About

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments... (more)

Overall

Beta: 2.10
Market Cap(Mil.): $82.28
Shares Outstanding(Mil.): 25.79
Dividend: --
Yield (%): --

Financials

BRIEF-Adma Biologics prices follow-on offering of 17.0 mln shares

* Adma Biologics Inc - ‍pricing of offering of approximately 17.0 million shares of its common stock at price of $2.15 per share​ Source text for Eikon: Further company coverage:

09 Nov 2017

BRIEF-ADMA Biologics now sees offering‍​ of 13.6 mln shares of common stock - SEC filing

* Now sees offering‍​ of 13.6 million shares of its common stock, up from previous filing of 10.2 million shares - SEC filing Source text: (http://bit.ly/2zmNV1L) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

09 Nov 2017

BRIEF-ADMA Biologics Q3 loss per share $0.59

* ADMA Biologics provides corporate update and reports third quarter 2017 financial results

04 Nov 2017

BRIEF-ADMA Biologics says ‍loss per share was $0.59 for fiscal quarter ended Sept 30​

* ADMA Biologics Inc says ‍for fiscal quarter ended September 30, loss per share was $0.59 - SEC filing​

04 Nov 2017

BRIEF-Adma Biologics Inc files for offering of up to $28.75‍​ million of common stock

* Adma Biologics Inc files for offering of up to $28.75‍​ million of common stock Source text: (http://bit.ly/2gvC2f8) Further company coverage:

12 Oct 2017

BRIEF-ADMA Biologics ‍enters into credit agreement for up to $40 mln with affiliated entities of Marathon Asset Management​

* ADMA Biologics Inc - ‍entered into a credit agreement for up to $40 million with affiliated entities of marathon asset management​

11 Oct 2017

BRIEF-ADMA Biologics Q2 loss per share $0.55

* ADMA Biologics provides corporate update and reports second quarter 2017 financial results

12 Aug 2017

BRIEF-U.S. Patent and Trademark Office issues immunotehrapy patent to Adma Biologics

* Adma Biologics - U.S. Patent and trademark office has issued to co U.S. Patent no. 9,714,283 which encompasses methods of providing immunotherapy to patients

01 Aug 2017

BRIEF-ADMA Biologics provides corporate timeline and activities update

* ADMA Biologics provides corporate timeline and activities update to stockholders

27 Jun 2017

BRIEF-ADMA Biologics Inc files for resale of 6.04 million shares of co's common stock

* ADMA Biologics Inc files for resale of 6.04 million shares of co's common stock by the selling shareholders Source text: (http://bit.ly/2twQ4Bo) Further company coverage:

17 Jun 2017

Competitors

  Price Chg
Baxter International Inc (BAX.N) $64.04 -0.21
Biotest AG (BIOG.DE) €21.00 -0.25
Biotest AG (BIOG_p.DE) €19.00 +0.25

Earnings vs. Estimates